---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-22-000014"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2022-02-16T23:59:59+00:00"
generated_at: "2026-06-27T07:28:02.321530+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA clears Tandem Diabetes t:slim X2 insulin pump to deliver bolus via smartphone app

## Summary
- FDA cleared t:slim X2 insulin pump to program and cancel bolus insulin doses using t:connect mobile app on iOS and Android.
- First smartphone app to receive FDA clearance for insulin delivery on both operating systems.
- Feature will be available via remote software update at no extra cost to new and in-warranty customers.
- Rollout begins spring with limited launch groups, expanded launch expected later summer.
- CEO John Sheridan highlights this as one of most requested feature enhancements for Control-IQ technology.

## SEC filing metadata
- accession: 0001438133-22-000014
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2022-02-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813322000014/0001438133-22-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813322000014/tndm-20220216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-22-000014
- JSON: https://secwatch.observer/filing/0001438133-22-000014.json
- Plain text: https://secwatch.observer/filing/0001438133-22-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.